“Efficacy and Safety of Bimekizumab in Patients with Moderate to Severe Plaque Psoriasis: Results from BE VIVID, a 52-Week Phase 3, Randomized, Double-Blinded, Ustekinumab- and Placebo-Controlled Study” (2020) SKIN The Journal of Cutaneous Medicine, 4(6), p. s82. doi:10.25251/skin.4.supp.82.